We report a rare case of a schneiderian papilloma ofthe nasopharynx. Because this tumor is locally invasive, has a tendency to recur, and can undergo malignant transformation, it should be completely excised. It is possible to completely remove such a tumor in a minimally invasive way by using a combination of transnasal and transoral approaches and high-resolution angled endoscopes and other suitably designed instruments.
was a chronic smoker, and he had a history of allergy to penicillin. Examination revealed the presence of a polypoid mass arising from the left postnasal space in the region of the eustachian tube cushion. An initial punch biopsy of the mass under local anesthesia via the oropharynx identified a squamous metaplasia with mild to moderate dysplasia.
The entire lesion was completely excised under general anesthesia transnasally and trans orally with rigid nasoendoscopic guidance. A 4-mm rigid nasoendoscope (0°and 30°) was used to view the lesion in the nasopharynx (figure I) . A decongestant was applied to the lesion . A sickle scalpel and endoscopic sinus surgical scissors were used transnasally to excise the upper half of the lesion, leaving at least 0.5 mm of clear margin . Via the oropharynx, the soft palate was superiorly retracted, which allowed the lower half of the lesion to be exposed. The lower half was then similarly excised with a scalpel.
Histologic analysis of the lesion confirmed that it was a schneiderian papilloma (figure 2). The patient recovered without complications, and after more than 2 years of follow-up , he is well and manifests no evidence of recurrence .
Discussion
According to Sulica et ai, the ectopic appearance of a schneiderian papilloma outside the sinonasal tract has been reported in cervical lymph nodes, the pharynx , the middle ear, and the mastoid.' Knowledge of the embryology of the upper aerodigestive tract helps the surgeon understand the nature of this disease in ectopic sites.
The nasal placodes develop as early as the third week of gestation . They subsequently invaginate centrally to become the nasal pits by the fifth week. The ectodermally derived epithelium that lines these ingrowths forms the schneiderian membrane. The fundus ofthese pits eventually meets the rostral end of the developing endodermlined pharynx. The resulting buccona sal membrane, consisting of a layer each of ectoderm and endoderm, sepa- 
AcipHex· rabeprazo/e sodiJm 20-MGTABLETS
Before prescribing, please consul t completeprescribing informationof whichthefollowi ngisabrief summary. INDICATIONS ANDUSAGE Healing01 ErosiveorUlcerative GastroesophagealRefluxDi sease(GERO) ACIPHEX' is indicated lorshort-term (4to 8 weeks)treatment inthehealing and symptomatic reliefoferosive or ulcerat ive gastroesophageal reflux disease (GERD). For those patients whohave not heal ed alter 8 weeks of treatment . anadditional8-weekcourseof ACIPHEX' maybeconsidered. Maintenance of Healing ofErosive orUlcerativeGastroesophageal Reltux Disease(GERD) ACIPHEX' isindi catedlormaintaininghealing andreductioninrelapse ratesotheartburn symptoms inpatientswith erosive orulcerative gastroesophageal refl uxdisease(GERDMaintenance) _ Healing 01Duodenal Ulcers ACIPHEX' is indicated lor short-term (up to lour weeks) treatment in the healing and symptomatic reliet of duodenalulcers. Most pat ientshealwi thinfour weeks. Tr eatment 01 Pathological Hypersecretory Conditions, IncludingZollinger-Ellison Syndrome ACIPHEX' is indicated for the long-term treatm ent of pathological hypersecret ory conditionsincluding Zollinger -Ellison syndrome. CDNTRAI NDICATIDNS Rabeprazoleiscontraindicated inpatients withknownhypersensitivitytorabeprazole, substituted benzimidazoles orto any component ofthe formulation. PRECAUTlDNS General Symptomaticresponsetotherapywi thrabeprazoledoesnot precludethe presenceofgastricmalignancy . Patients wi th healed GERD were treated for up to 4Dmonths with rabeprazoleand monitored wi th ser ial gastr ic biopsies. Patientswi thout H. pylori intection(221 of326pat ients) had noclinicalty important pathologic changes in the gastric mucosa. Patients wit h H. pylori intection at baseline (ID5 ot 326 patients) had mild or moderate inltammation inthe gastricbody ormildinfl ammation inthe gastricantrum. Pat ient swithmildgrades otinfectionor inltammation inthe gastricbody tended tochange tomoderate, whereasthose graded moderate atbaselinetended toremainstable. Pat ientswit hmildgradesofinfectionor inltammationinthegast ricantrumtendedtoremainstable. At baseline8%ot patients hadatrophyofglands inthe gastricbodyand15%had atrophy inthe gastri c antrum. At endpoint, 15%of patients had atrophyof glands in thegastric body and 11% had at rophy in the gastri c antrum. Approximately 4%ofpatients had intestinal metaplasia atsomepoint during follow-up, but no consistent changes were seen. Inlormationlor Patients Patientsshould be cautioned that ACIPHEX' delayed-releasetablets shouldbe swallowed whole. Thetablets should not be chewed,crushed, or split. DrugInteractions Rabeprazoleismetabol ized bythe cytochrome P450 (CYP450) drug metabolizing enzyme system. Studies inheallhy subjects have shown that rabeprazoledoes not haveclinically signi licant interactions withother drugs metabolized by theCYP450 system, such as wartarin and theophyllinegiven as singleoral doses, diazepam asa si ngleintravenous dose, andphenyt oingivenas asi ngle intravenous dose (withsupplemental oral dosing). Invitro incubat ions employing human li ver mi crosomes indicatedthat rabeprazoleinhiMedcyclosporine metabolism wi thanIC" of 62micromolar, a concentrationthat isover 50timeshigherthan the C"" inhealthyvolunteersfollowing 14days ofdosing Vltth 20mgof rabeprazole.Thisdegree of inhibition issimilar tothat byomeprazole atequivalent concentrations. Rabeprazole produces sustained inhibition of gastric acid secretion. An interacticn with com poundswhich are dependentongast ricpH forabsorptionmayoc curduetothe magnitudeof acidsuppression observedwit hrabeprazole. For example, in normal subjects, co-administration of rabeprazole 20mg 00 resulted in an approximately 30% decrease in the bioavailability 01ketoconazole and increases in the AUC and C_ for digoxin 0119%and 29%, respect ivel y. Therefore, patientsmayneedtobe monitored whensuchdrugsare taken concomitantly withrabeprazole. Co-administration of rabeprazoleand antacids produced noclinically relevant changes in plasma rabeprazo le concentrations. Carcinog enesis,Mutagenesis, Impairment of Fertili ty Ina88/104-week carcinogenicity st udy inCD-I mice, rabeprazoleatoral doses up to100mg/kg/day didnot produce any increased tumor occu rrence. The highest tested dose produced a systemic exposure to rabeprazole(AUC) of 1.40pg' hr/mLwhichis1.6times the human exposure (plasma AUc,.. =0.88 pg'hr/mL) at the recommended dose forGERD (20 mglday). In a 104-week carcinogenicity studyinSprague-Dawl ey rats, males wer etreated with oral doses 01 5, 15, 30and 60 mglkglday and lemales wi th 5, 15 , 30, 60and 120 mglkglday. Rabeprazoleproduced gastricenterochromaffin-like (ECL)cell hyperplasiainmaleand femalerats and ECLcelt carcinoidtumors intemale rats at alldoses including thelowest testeddose. Thelowest dose(5 mglkglday) producedasystemic exposure to rabeprazole (AU C) of about 0.1 pg'hr/mLwhich isabout 0.1 times thehuman exposureatthe recommended dose lor GERD. In male rats, notreatment related tumors were observed at doses upto 60 mg/kgl day producing a rabeprazoleplasmaexposure(AUC) ot about0.2pg' hr /mL (0. 2times the human exposureatthe recommendeddose 1 0rGERD). Rabeprazolewas positiveintheAmes test, the Chinese hamst erovary cell (CHOIHGPRT)forward gene mutationtest and the mouse lymphomacelt (L5178YfTK+I-) forvl3f d gene mut at ion test.Its demethylated-met abolitewas also positi veinthe Ames test. Rabeprazole wasnegative inthe invit roChinese hamsterlungceltchromosome aber ration test, the in vivo mouse micronucleus test, and the in vivo and ex vi vo rat hepatocyte unscheduled DNAsynthesis (UDS) tests. Rabeprazol eatintravenous doses up to 30 mg/kg/day (plasma AUC of 8.8 pg'hr/mL, about 10 times the human exposure at the recommended dose for GERD) wasfound tohaveno effect onfertil ityand reproductive pertormanceof male and female rats. Pregnancy TeralogenicEffects. Pregnancy Category 8: Teratol ogystudies havebeenpertormed inratsat int ravenous doses up to 50mglk gl day (plasma AUC of 11.8pg'hr/mL, about 13times thehuman exposureat the recommendeddosefor GERD) andrabbitsatintravenous dosesup10 30mglkglday (plasmaAUC of 7.3pg' hr/mL,about 8times thehuman exposure at the recommended dosetor GERD) andhave revealednoevidenceof impairedfertilityorharm tothefetus duetorabepr azole. Ther eare, however, noadequat eand well-cont rolledstudies inpregnantwomen. Becauseanimal reproductionstudies are notalways pred ictiveof human response, thisdrug should be usedduring pregnancyonly if clearlyneeded. Nursing Mothers Foltowingintravenousadminist rationof " C-Iabeledrabeprazole tolact ating rats, radi oact ivi tyinmilkreached levelsthat were2-to 7-fold higherthan level s in thebl ood. It is notknown if unmelaboli zed rabeprazoleisexcreted in human breast milk. Administration of rabeprazoleto rats in lategest ation and during lactation atdoses of 400 mg/kglday (about 195-times the human dose based on mgl m') resulted indecreases in body weight gainof the pups. Since many drugs are excreted in milk, and because 01 the potential tor adverse reactions to nursing infants from rabeprazole, a decision should be madeto discontinue nursing or discontinue the drug, taking into account the importance ofthe drugtothemother. PediatricUse Thesafetyand elt ectivenessotrabeprazoleinpediatri cpat ientshavenot beenestablished.
UseinWomen
Duodenal ulcer and erosive esophagitis healing rates in women are similar to those in men. Adverseevents and laboratory test abnormalities inwomen occurred at rates similartothose inmen. Geri atricUse Ofthetotalnumber 01 subjects in clinical studies of ACIPHEX' , 19% were 65 years and over , while4% wer e 75 years and over. Nooverall dilt erences insafety or eltectiveness wereobserved between thesesubjects andyounger subjects, and ot her reported clinical exper iencehas not identilied differences in responses bet ween theel derlyand younger patient s, but greatersensitivity of some older individualscannotbe ruledout. ADVERSE REACTIONS Worldwide, over 2900 patients have been treated with rabeprazole in Phase fl-III clinical trials involving various dosagesand durations of treatment. Ingeneral, rabeprazole treatmenthas beenwell-tolerated inboth short-term and long-term trials.Theadv er seevents rates wer egenerallysimilar between the 10and20mg doses. Incidence inControlledNorth American and EuropeanClinicalTrials Inananal ysisofadverse eventsassessedas possibl yor probablyrelat ed totreatment appear ingingreater than1% otACIPHEX' pat ientsandappearing withgreaterfrequencythanpl aceboincontrolledNorth Amer icanandEuropean trials, theincidence 01 headache was 2.4%(n=15521 for ACIPHEX' versus1. 6%(n=258) for pl acebo. Inshort and long-term st udies, the lollowing adverse events, regar dless ot causality, were reported in ACIPHEX'treated patients. Rare events are thosereported inS111000 patients. Borly as a Whole: asthenia. fever , allergic reaction. chills, malaise. chest pain substemal, neck rigidity, photosenstt ivity reaction. Rare: abdomen enlarged, lace edema, hangovereffect. In controlled clinical studies, 3/1456 (0.2%)patients treated with rabeprazoleand'2l237 (0.8%) patients treated with placebo developedtreatment -emer gent abnormalities (which wer eeither new on studyorpresent atstudy entry with an increase of 1.25 x baseline value) inSGOT (AST), SGPT (ALT), or both. None ofthe three rabeprazole patients experienced chills, tever, right upperquadrant pain, nausea orjaundice. Post -MarketingAdverse Even/s: Addi tionaladverse event s reported trom worldwide marketing experience with rabeprazolesodium are: sudden death, comaand hyper ammonemia, jaundice, rhabdomyolysis, di sorientationand deli rium, anaphylaxi s, angioedema, bull ous and otherdrug eruptions of theskin, inter stitial pneumonia, and TSH el evations. Inmost instances, the relationship to rabeprazolesodium was unclear. Inaddition, agranulocytosis, hemolytic anemia, leukopenia, pancytopenia, and thrombocytopeniahavebeenreported. OVERDO SAGE Because strat egies for the management 01overdos eare continually evolving, it is advisable 10 co ntact a Poison Control Centertodetermine the latest recommendat ionsforthe management 01 anoverdoseofanydrug_There has been no experiencewith~r ge over doses withrabeprazole. Seven reportsof accidental over dosage withrabeprazole havebeenreceived. Themaximum reported overdosewas 80mg.Therewerenocli nical signsorsympt omsassociated withany reported overdose. PatientswithZolli nger -Ellison syndromehave been treated wi thupto12 0mg rabeprazole 00. No specificantidotefor rabeprazole is known. Rabeprazoleis extensively protein bound and is not readily dialyzable.Inthe event otoverdosage, treatmentshouldbe symptomatic and supportive. Singleoral doses ofrabeprazole at786mg/kg and 1024 mg/kg were lethal to mice and rats, respectively. Thesingle oral dose 01 2000 mg/kg was not lethalto dogs. Themajor symptoms otacutetoxicity we re hypoactivity, labored respiration, lateral or prone positionand convulsion inmice and rats and watery diarrhea, tremor, convulsion and comaindogs. rates the two compartments. Thi s structure eventually breaks down , allowing for communication between the two cavities. By 10 weeks, the growth of the later al palatal shelves separates the nasal and oral compa rtments, and the developing septum divides the nasal cavity into right and left halves . The choanae represent the water shed area between ectodermally and endodermally derived epithelia. This process occasionally results in the migration or incorporation of schneideri an membrane into areas where it is not normally found . Subsequent inflammation of this tissue-either by environmental, viral, or other agentscan result in the development of a papillom a.' In a previous report of nasopharyngeal schneiderian papilloma, Astor et al described patien ts who had similar lesions in the nasal cavity.' Our patient had a solitary nasopha ryngeal schneiderian papillom a that did not involve the nasal cavity. It is interesting that this tumor was firm , had a smooth surface, and was not associated with any significant contact bleeding. These findin gs are in contrast with the typical characteristics of schneiderian papillomas in the sinonasal tract , which tend to be friabl e and papill omatou s and bleed easily when touched. v' The case of our patient also illustrates the limitations of surface punch biopsies, which do not always yield a true histologic diagnosis.
Because schneiderian tumors are locally invasive, have a tendency to recur, and can undergo malignant transformation, they should be completely excised. Traditionally, the intranasal approa ch had generally been considered an unsafe method of removing a schneiderian papilloma from the nose . Because this method is limited by inadequate visualiz ation and access, it has resulted in recurrence rates as high as 60%.4 More radic al operationssuch as lateral rhinotomy. ' midfa cial deglov ing," and Denke r' s appro ach/-c-have been used to provide better access. However, these open approaches are associated with increased morbidity.
In recent years, with the advent of endoscopic sinus surgery, high-resolution angled endos cope s and suitably designed instruments have provided excellent visualization and access to the sinonasal regions. Originally used for treating sinusitis and nasal polyposis, these transnasal endoscopic approaches have recently been used for the remov al of schneiderian papillom as from the sinonasal region with good results."
There are no reports of endo scopic techniques being used to treat schneiderian papillomas of the nasopharynx. Because nasopharyngeal schneiderian papillomas are rare, publi shed recommendations on how they should be managed are scarce. As with sinonasal schneiderian papillomas, the goal of treatment should be comp lete remo val with minimal morbidity.' Wolff et al described a case of nasopharyngeal schneiderian papilloma that was succes sfully removed via a midline soft palate incision ." Minimally invasive exci sion of lesions in the nasopharynx via intranasal and intraoral routes in the past have been hampered by poor visualization, access, and instrumentation. These limitations can be overcome with the use of high-resolution straight and angled endoscopes and endoscopic sinus surgery instruments , as illustrated by our case. In our patient, we had no difficulty in completely removing the sch neiderian papilloma from the nasopharynx with straight and angled endo scopic sinus instruments via a combined transn asal and trans oral approach . The use of the instruments provided excellent visualization and control. Sanderson and Knegt reported that recurrence of schneiderian papillomas almost always occurs within 2 years of the original operation, often within month s.' Our patient has been observed for more than 2 years and has shown no evidence of recurrence.
